The length of treatment of aggressive non-Hodgkin's lymphomas established according to the international prognostic index score: Long-term results of the GISL LA03 study

European Journal of Haematology

Volumn 76, Issue 3, 2006, Pages 217-229

  Federico, Massimo ^a,k   Luminari, Stefano ^a   Gobbi, Paolo G ^b   Sacchi, Stefano ^a   Di Renzo, Nicola ^c   Lombardo, Marco ^d   Merli, Francesco ^e   Baldini, Luca ^f   Stelitano, Caterina ^g   Partesotti, Giovanni ^h   Polimeno, Giuseppe ⁱ   Montanini, Antonella ^a   Mammi, Caterina ^a   Brugiatelli, Maura ^j  

^a UNIVERSITY OF MODENA AND REGGIO EMILIA   (Italy)

^b UNIVERSITY OF PAVIA   (Italy)

^c REFERRAL CANCER CENTER OF BASILICATA   (Italy)

^d SPIRITO SANTO HOSPITAL   (Italy)

^e S MARIA NUOVA HOSPITAL   (Italy)

^f IRCCS   (Italy)

^g BIANCHI MELACRINO MORELLI HOSPITAL   (Italy)

^h Ospedale Civile   (Italy)

ⁱ MIULLI GENERAL HOSPITAL   (Italy)

^j Azienda Ospedaliera Papardo   (Italy)

^k UNIVERSITY OF MODENA AND REGGIO EMILIA   (Italy)

more..

Author keywords

Aggressive NHL; Epidoxorubicin; Idarubicin; IPI; ProMACE CytaBOM

Indexed keywords

ANTINEOPLASTIC AGENT; BLEOMYCIN; COTRIMOXAZOLE; CYCLOPHOSPHAMIDE; CYTARABINE; EPIRUBICIN; ETOPOSIDE; FLUCONAZOLE; FOLINIC ACID; GRANULOCYTE COLONY STIMULATING FACTOR; IDARUBICIN; KETOCONAZOLE; METHOTREXATE; PREDNISONE; VINCRISTINE;

ADOLESCENT; ADULT; AGED; ANEMIA; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER RADIOTHERAPY; CANCER REGRESSION; CANCER RELAPSE; CANCER SURVIVAL; CAUSE OF DEATH; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE FREE SURVIVAL; DISEASE SEVERITY; DOSE RESPONSE; DRUG DOSE REDUCTION; DRUG DOSE REGIMEN; FEBRILE NEUTROPENIA; FEMALE; FOLLOW UP; HUMAN; INFECTION; LONG TERM CARE; LUNG TOXICITY; MAJOR CLINICAL STUDY; MALE; NONHODGKIN LYMPHOMA; PHASE 3 CLINICAL TRIAL; PRESCRIPTION; PRIORITY JOURNAL; PROGNOSIS; RANDOMIZED CONTROLLED TRIAL; SURVIVAL RATE; SURVIVAL TIME; THROMBOCYTOPENIA; TREATMENT OUTCOME;

EID: 33645094668     PISSN: 09024441     EISSN: 16000609     Source Type: Journal    
DOI: 10.1111/j.1600-0609.2005.00609.x     Document Type: Article

References (38)

1. D e V ita VT Jr H ellman S R osemberg SA. Lymphomas in Cancer In Principles and Practice of Oncology Philadelphia Lippincott Williams and Wilkins 2001 2215 2388
2. E lias L P ortlock CS R osenberg SA. Combination chemotherapy of diffuse histiocytic lymphoma with cyclophosphamide, adriamycin, vincristine and prednisone (CHOP) Cancer 1978 42 1705 1710
3. S karin AT C anellos GP R osenthal DS C ase DC Jr M ac I ntyre JM P inkus GS M oloney WC F rei E. III. Improved prognosis of diffuse histiocytic and undifferentiated lymphoma by use of high dose methotrexate alternating with standard agents (M-BACOD) J Clin Oncol 1983 1 91 98
4. K limo P C onnors JM. MACOP-B chemotherapy for the treatment of diffuse large-cell lymphoma Ann Intern Med 1985 102 596 602
5. L ongo DL D e V ita VT J r D uffey PL et al. Superiority of ProMACE-CytaBOM over ProMACE-MOPP in the treatment of advanced diffuse aggressive lymphoma: results of a prospective randomized trial J Clin Oncol 1991 9 25 38
6. C oiffier B G isselbrecht C H erbrecht R T illy H B osly A B rousse N. LNH-84 regimen: a multicenter study of intensive chemotherapy in 737 patients with aggressive malignant lymphoma J Clin Oncol 1989 7 1018 1026
7. F isher RI G aynor ER D ahlberg S O ken MM G rogan TM M ize EM G lick JH C oltman CA Jr. M iller TP. Comparison of a standard regimen (CHOP) with three intensive chemotherapy regimens for advanced non-Hodgkin's lymphoma N Engl J Med 1993 328 1002 1006
8. C ooper IA W olf MM R obertson TI et al. Randomized comparison of MACOP-B with CHOP in patients with intermediate-grade non-Hodgkin's lymphoma. The Australian and New Zealand Lymphoma Group J Clin Oncol 1994 12 769 778
9. M ontserrat E G arcia -C onde J V inolas N et al. CHOP vs. ProMACE-CytaBOM in the treatment of aggressive non-Hodgkin's lymphomas: long-term results of a multicenter randomized trial (PETHEMA: Spanish Cooperative Group for the Study of Hematological Malignancies Treatment, Spanish Society of Hematology) Eur J Haematol 1996 57 377 383
10. G ordon LI H arrington D A ndersen J et al. Comparison of a second-generation combination chemotherapeutic regimen (m-BACOD) with a standard regimen (CHOP) for advanced diffuse non-Hodgkin's lymphoma N Engl J Med 1992 327 1342 1349
11. G ianni AM B regni M S iena S et al. High-dose chemotherapy and autologous bone marrow transplantation compared with MACOP-B in aggressive B-cell lymphoma N Engl J Med 1997 336 1290 1297
12. C oiffier B L epage E B riere J et al. CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma N Engl J Med 2002 346 235 242
13. The International Non-Hodgkin's Lymphoma Prognostic Factors Project A predictive model for aggressive non-Hodgkin's lymphoma N Engl J Med 1993 329 987 994
14. S ilingardi V F ederico M C avanna L et al. ProMECE-CytaBOM vs MACOP-B in advanced aggressive non-Hodgkin's lymphoma: long-term results of a multicenter study of the Italian lymphoma study group (GISL) Leuk Lymphoma 1995 17 313 320
15. F ederico M C lo V B rugiatelli M et al. Efficacy of two different ProMACE-CytaBOM derived regimens in advanced aggressive non-Hodgkin's lymphoma. Final report of a multicenter trial conducted by GISL Haematologica 1998 83 800 811
16. L ongo DL D uffey PL J affe ES R affeld M H ubbard SM F isher RI W ittes RE D e V ita VT Jr. Y oung RC. Diffuse small noncleaved-cell, non-Burkitt's lymphoma in adults: a high-grade lymphoma responsive to ProMACE-based combination chemotherapy J Clin Oncol 1994 12 2153 2159
17. G ordon LI Y oung M W eller E H abermann TM W inter JN G lick J G hosh C F lynn P C assileth PA. A phase II trial of 200% ProMACE-CytaBOM in patients with previously untreated aggressive lymphomas: analysis of response, toxicity, and dose intensity Blood 1999 94 3307 3314
18. C assi E B utti C B aldini L et al. A cooperative study on ProMACE-CytaBOM in aggressive non-Hodgkin's lymphomas Leuk Lymphoma 1994 13 111 118
19. G obbi PG G hirardelli ML A vanzini P et al. A variant of ProMACE-CytaBOM chemotherapy for non-Hodgkin's lymphoma with threefold higher drug dose size but identical cumulative dose intensity. A pilot study of the Italian lymphoma study group (GISL) Haematologica 2000 85 263 268
20. Italian Multicentre Breast Study with Epirubicin Phase III randomized study of fluorouracil, epirubicin, and cyclophosphamide v fluorouracil, doxorubicin, and cyclophosphamide in advanced breast cancer: an Italian multicentre trial J Clin Oncol 1988 6 976 982
21. C ase DC Jr. H ayes DM G erber M G ams R E rvin TJ D orsk BM. Phase II study of oral idarubicin in favorable histology non-Hodgkin's lymphoma Cancer Res 1990 50 6833 6835
22. H ryniuk W B ush H. The importance of dose intensity in chemotherapy of metastatic breast cancer J Clin Oncol 1984 2 1281 1288
23. M artelli M G herlinzoni F D e Renzo A et al. Early autologous stem-cell transplantation versus conventional chemotherapy as front-line therapy in high-risk, aggressive non-Hodgkin's lymphoma: an Italian multicenter randomized trial J Clin Oncol 2003 21 1255 1262
24. Z inzani PL M artelli M M agagnoli M et al. How do patients with aggressive non-Hodgkin's lymphoma treated with third-generation regimens (MACOP-B and F-MACHOP) fare in the long-term Haematologica 1999 84 996 1001
25. J erkeman M A nderson H C avallin -S tahl E et al. CHOP versus MACOP-B in aggressive lymphoma - a Nordic Lymphoma Group randomised trial Ann Oncol 1999 10 1079 1086
26. T illy H L epage E C oiffier B et al. Intensive conventional chemotherapy (ACVBP regimen) compared with standard CHOP for poor-prognosis aggressive non-Hodgkin lymphoma Blood 2003 102 4284 4289
27. M eyer RM H ryniuk WM G oodyear MD. The role of dose intensity in determining outcome in intermediate-grade non-Hodgkin's lymphoma J Clin Oncol 1991 9 339 347
28. M eyer RM Q uirt IC S killings JR et al. Escalated as compared with standard doses of doxorubicin in BACOP therapy for patients with non-Hodgkin's lymphoma N Engl J Med 1993 329 1770 1776
29. W ilson WH G rossbard ML P ittaluga S et al. Dose-adjusted EPOCH chemotherapy for untreated large B-cell lymphomas: a pharmacodynamic approach with high efficacy Blood 2002 99 2685 2693
30. G ordon LI A nderson J H abermann TM W inter JN G lick J S childer RJ C assileth P. Phase I trial of dose escalation with growth factor support in patients with previously untreated diffuse aggressive lymphomas: determination of the maximum-tolerated dose of ProMACE-CytaBOM J Clin Oncol 1996 14 1275 1281
31. R eyes F L epage E G anem G et al. ACVBP versus CHOP plus radiotherapy for localized aggressive lymphoma N Engl J Med 2005 352 1197 1205
32. S hipp MA N euberg D J anicek M C anellos GP S hulman LN. High-dose CHOP as initial therapy for patients with poor-prognosis aggressive non-Hodgkin's lymphoma: a dose-finding pilot study J Clin Oncol 1995 13 2916 2923
33. T anosaki R O kamoto S A katsuka N et al. Dose escalation of biweekly cyclophosphamide, doxorubicin, vincristine, and prednisolone using recombinant human granulocyte colony stimulating factor in non-Hodgkin's lymphoma Cancer 1994 74 1939 1944
34. B ergmann L K arakas T L autenschlager G J ager E K nuth A M itrou PS H oelzer D. Vincristine, doxorubicin, cyclophosphamide, prednisone and etoposide (VACPE) in high-grade non-Hodgkin's lymphoma - a multicenter phase II study Ann Oncol 1995 6 1019 1024
35. P freundschuh M T rumper L K loess M et al. Two-weekly or 3-weekly CHOP chemotherapy with or without etoposide for the treatment of young patients with good-prognosis (normal LDH) aggressive lymphomas: results of the NHL-B1 trial of the DSHNHL Blood 2004 104 626 633
36. P freundschuh M T rumper L M a D et al. Randomized Intergroup Trial of First Line Treatment for Patients ≤60 years with Diffuse Large B-Cell Non-Hodgkin's Lymphoma (DLBCL) with a CHOP-Like Regimen With or Without the Anti-Cd20 Antibody Rituximab - Early Stopping After the First Interim Analysis in ASCO New Orleans, LA, US American Society of Clinical Oncology 2004
37. V itolo U C ortellazzo S L iberati AM et al. Intensified and high-dose chemotherapy with granulocyte colony-stimulating factor and autologous stem-cell transplantation support as first-line therapy in high-risk diffuse large-cell lymphoma J Clin Oncol 1997 15 491 498
38. P freundschuh M. R-CHOP in Young, Low-Risk Patients: The MInT Study in ASH. S Diego American Society of Hematology 2003